Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.65 EUR -2.99% Market Closed
Market Cap: 14.7m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

EV/OCF
Enterprise Value to OCF

-0.9
Current
-0.4
Median
5.7
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-0.9
=
Enterprise Value
8.6m EUR
/
Operating Cash Flow
-9.7m EUR
All Countries
Close
Market Cap EV/OCF
BE
Celyad Oncology SA
XBRU:CYAD
14.7m EUR -0.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -237 522.5
US
Abbvie Inc
NYSE:ABBV
320.1B USD 22.5
US
Amgen Inc
NASDAQ:AMGN
150.5B USD 27.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD -133.7
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 10.9
US
Epizyme Inc
F:EPE
94.1B EUR -474
AU
CSL Ltd
ASX:CSL
135.4B AUD 35.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD 17.9
US
Seagen Inc
F:SGT
39.3B EUR -74.2
NL
argenx SE
XBRU:ARGX
34.5B EUR -127.6
 
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/OCF: 22.7
Negative Multiple: -0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -237 522.5
US
Abbvie Inc
NYSE:ABBV
22.5
US
Amgen Inc
NASDAQ:AMGN
27.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -133.7
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474
AU
CSL Ltd
ASX:CSL
35.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -74.2
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.6

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A

See Also

Discover More